Posted by Michael Wonder on 30 Jan 2017
CADTH recommends UCB's Brivlera
25 January 2017 - CADTH's first outcome for 2017 is in favour of the reimbursement of brivaracetam.
The CADTH CDEC has recommended that brivaracetam be reimbursed for adjunctive therapy in the management of partial-onset seizures in adult patients with epilepsy who are not satisfactorily controlled with conventional therapy, if certain clinical criteria and conditions are met.
